請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/58047完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 劉振軒(Chen-Hsuan Liu) | |
| dc.contributor.author | Jia-Wei Jiang | en |
| dc.contributor.author | 江家瑋 | zh_TW |
| dc.date.accessioned | 2021-06-16T08:05:04Z | - |
| dc.date.available | 2014-07-08 | |
| dc.date.copyright | 2014-07-08 | |
| dc.date.issued | 2014 | |
| dc.date.submitted | 2014-06-26 | |
| dc.identifier.citation | 1. Aaronson RM, Graven KK, Tucci M, McDonald RJ, Farber HW. Non-neuronal enolase is an endothelial hypoxic stress protein. J Biol Chem 270: 27752-27757, 1995.
2. Abadie JJ, Amardeilh MA, Delverdier ME. Immunohistochemical detection of proliferating cell nuclear antigen and Ki-67 in mast cell tumors from dogs. J Am Vet Med Assoc 215: 1629-1634, 1999. 3. Al‐Sarraf R, Mauldin GN, Patnaik AK, Meleo KA. A prospective study of radiation therapy for the treatment of grade 2 mast cell tumors in 32 dogs. J Vet Intern Med 10: 376-378, 1996. 4. Altenberg B, Greulich KO. Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics 84: 1014-1020, 2004. 5. Aronsohn MG, Carpenter JL. Distal extremity melanocytic nevi and malignant melanomas in dogs. J Am Anim Hosp Assoc 26: 605-612, 1990. 6. Arza B, Felez J, Lopez-Alemany R, Miles LA, Munoz-Canoves P. Identification of an epitope of alpha-enolase (a candidate plasminogen receptor) by phage display. Thromb Haemost 78: 1097-1103, 1997. 7. Bateman KE, Catton PA, Pennock PW, Kruth SA. 0–7–21 radiation therapy for the treatment of canine oral melanoma. J Vet Intern Med 8: 267-272, 1994. 8. Bergin IL, Smedley RC, Esplin DG, Spangler WL, Kiupel M. Prognostic evaluation of Ki67 threshold value in canine oral melanoma. Vet Patho 48: 41-53, 2011. 9. Bhargava A, Saigal S, Chalishazar M. Histopathological grading systems in oral squamous cell carcinoma: a review. J Int Oral Health 2: 1-10, 2010. 10. Birchard S, Carothers M. Aggressive surgery in the management of oral neoplasia. Vet Clin North Am Small Anim Pract 20: 1117-1140, 1990. 11. Bolon B, Mays MC, Hall B. Characteristics of canine melanomas and comparison of histology and DNA ploidy to their biologic behavior. Vet Patho 27: 96-102, 1990. 12. Bortnowski HB, Rosenthal RC. Gastrointestinal mast cell tumors and eosinophilia in two cats. J Am Anim Hosp Assoc 28: 271-275, 1992. 13. Bostock DE. Neoplasms of the skin and subcutaneous tissues in dogs and cats. Br Vet J 142: 1-19, 1986. 14. Bostock DE. Prognosis after surgical excision of canine melanomas. Vet Pathol 16: 32-40, 1979. 15. Bostock DE, Crocker J, Harris K, Smith P. Nucleolar organiser regions as indicators of post-surgical prognosis in canine spontaneous mast cell tumours. Br J Cancer 59: 915-918, 1989. 16. Briffod M, Hacene K, Le Doussal V. Immunohistochemistry on cell blocks from fine-needle cytopunctures of primary breast carcinomas and lymph node metastases. Mod Pathol 13: 841-850, 2000. 17. Brodey RS. Alimentary tract neoplasms in the cat: a clinicopathologic survey of 46 cases. Zahnarztl Prax 17: 74-80, 1966. 18. Bryne M, Koppang HS, Lilleng R, Stene T, Bang G, Dabelsteen E. New malignancy grading is a better prognostic indicator than Broders' grading in oral squamous cell carcinomas. J Oral Pathol Med 18: 432-437, 1989. 19. Burrows AK, Lee EA, Shaw SE, Robertson ID, Clark WT. Skin neoplasms of cats in Perth. Aust Vet Pract 24: 11-15, 1994. 20. Carpenter JL, Andrews LK, Holzworth J. Tumors and tumor-like lesions. In: Holzworth J, ed. Diseases of the cat: medicine and surgery. 1st ed. W.B. Saunders, Philadelphia, 406-596, 1987. 21. Carter RF, Valli VE, Lumsden JH. The cytology, histology and prevalence of cell types in canine lymphoma classified according to the National Cancer Institute Working Formulation. Can J Vet Res 50: 154-164, 1986. 22. Chang GC, Liu KJ, Hsieh CL, Hu TS, Charoenfuprasert S, Liu HK, Luh KT, Hsu LH, Wu CW, Ting CC. Identification of alpha-enolase as an autoantigen in lung cancer: Its overexpression is associated with clinical outcomes. Clin Cancer Res 12: 5746-5754, 2006. 23. Charafe‐Jauffret E, Tarpin C, Bardou VJ, Bertucci F, Ginestier C, Braud AC, Puig B, Geneix J, Hassoun J, Birnbaum D. Immunophenotypic analysis of inflammatory breast cancers: identification of an ‘inflammatory signature’. J Pathol 202: 265-273, 2004. 24. Chhatwal GS. Anchorless adhesins and invasins of Gram-positive bacteria: a new class of virulence factors. Trends Microbiol 10: 205-208, 2002. 25. Chu PY, Hsu NC, Liao AT, Shih NY, Hou MF, Liu CH. Overexpression of α-enolase correlates with poor survival in canine mammary carcinoma. BMC Vet Res 7: 62, 2011. 26. Clark WH, From L, Bernardino EA, Mihm MC. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 29: 705-727, 1969. 27. Court EA, Watson AD, Peaston AE. Retrospective study of 60 cases of feline lymphosarcoma. Aust Vet J 75: 424-427, 1997. 28. Dobson JM, Blackwood LB, McInnes EF, Bostock DE, Nicholls P, Hoather TM, Tom BD. Prognostic variables in canine multicentric lymphosarcoma. J Small Anim Pract 42: 377-384, 2001. 29. Dobson JM, Scase TJ. Advances in the diagnosis and management of cutaneous mast cell tumours in dogs. J Small Anim Pract 48: 424-431, 2007. 30. Dorn CR, Taylor D, Schneider R. Sunlight exposure and risk of developing cutaneous and oral squamous cell carcinomas in white cats. J Natl Cancer Inst 46: 1073-1078, 1971. 31. Dorn CR, Taylor DO, Schneider R, Hibbard HH, Klauber MR. Survey of animal neoplasms in Alameda and Contra Costa Counties, California. II. Cancer morbidity in dogs and cats from Alameda County. J Natl Cancer Inst 40: 307-318, 1968. 32. Dudani AK, Cummings C, Hashemi S, Ganz PR. Isolation of a novel 45 kDa plasminogen receptor from human endothelial cells. Thromb Res 69: 185-196, 1993. 33. Edwards DS, Henley WE, Harding EF, Dobson JM, Wood JL. Breed incidence of lymphoma in a UK population of insured dogs. Vet Comp Oncol 1: 200-206, 2003. 34. Ettinger SN. Principles of treatment for canine lymphoma. Clin Tech Small Anim Pract 18: 92-97, 2003. 35. Feo S, Arcuri D, Piddini E, Passantino R, Giallongo A. ENO1 gene product binds to the c-myc promoter and acts as a transcriptional repressor: relationship with Myc promoter-binding protein 1 (MBP-1). FEBS Lett 473: 47-52, 2000. 36. Fontan PA, Pancholi V, Nociari MM, Fischetti VA. Antibodies to streptococcal surface enolase react with human α-enolase: implications in poststreptococcal sequelae. J Infect Dis 182: 1712-1721, 2000. 37. Fox LE, Rosenthal RC, Twedt DC, Dubielzig RR, MacEwen EG, Grauer GF. Plasma histamine and gastrin concentrations in 17 dogs with mast cell tumors. J Vet Intern Med 4: 242-246, 1990. 38. Frank JD, Reimer SB, Kass PH, Kiupel M. Clinical outcomes of 30 cases (1997–2004) of canine gastrointestinal lymphoma. J Am Anim Hosp Assoc 43: 313-321, 2007. 39. Freeman KP, Hahn KA, Harris FD, King GK. Treatment of dogs with oral melanoma by hypofractionated radiation therapy and platinum‐based chemotherapy (1987–1997). J Vet Intern Med 17: 96-101, 2003. 40. Frimberger AE, Moore AS, Rassnick KM, Cotter SM, O'Sullivan JL, Quesenberry PJ. A combination chemotherapy protocol with dose intensification and autologous bone marrow transplant (VELCAP‐HDC) for canine lymphoma. J Vet Intern Med 20: 355-364, 2006. 41. Fulcher RP, Ludwig LL, Bergman PJ, Newman SJ, Simpson AM, Patnaik AK. Evaluation of a two-centimeter lateral surgical margin for excision of grade I and grade II cutaneous mast cell tumors in dogs. J Am Vet Med Assoc 228: 210-215, 2006. 42. Gabor LJ, Malik R, Canfield PJ. Clinical and anatomical features of lymphosarcoma in 118 cats. Aust Vet J 76: 725-732, 1998. 43. Garrett LD, Thamm DH, Chun R, Dudley R, Vail DM. Evaluation of a 6‐month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med 16: 704-709, 2002. 44. Gieger TL, Theon AP, Werner JA, McEntee MC, Rassnick KM, DeCock HE. Biologic behavior and prognostic factors for mast cell tumors of the canine muzzle: 24 cases (1990–2001). J Vet Intern Med 17: 687-692, 2003. 45. Goldschmidt MH. Benign and malignant melanocytic neoplasms of domestic animals. Am J Dermatopathol 7: 203-212, 1985. 46. Goldschmidt MH, Hendrick MJ. Tumors of the skin and soft tissue. In: Meuten DJ, ed. Tumors in domestic animals. 4th ed. Blackwell Publishing Company, Iowa, 45-117, 2002. 47. Goldschmidt MH, Shofer FS. Squamous cell carcinoma. In: Skin tumors of the dog and cat. 3rd ed. Pergamon Press, Oxford, 37-49, 1992. 48. Gross TL, Ihrke PJ, Walder EJ, Affolter VK. Epidermal tumors. In: Skin diseases of the dog and cat: Clinical and Histopathologic Diagnosis. 2nd ed. Wiley-Blackwell, Iowa, 562-603, 2005. 49. Gross TL, Ihrke PJ, Walder EJ, Affolter VK. Melanocytic tumors. In: Skin diseases of the dog and cat: Clinical and Histopathologic Diagnosis. 2nd ed. Wiley-Blackwell, Iowa, 813-836, 2005. 50. Hahn KA, DeNicola DB, Richardson RC, Hahn EA. Canine oral malignant melanoma: prognostic utility of an alternative staging system. J Small Anim Pract 35: 251-256, 1994. 51. Hahn KA, Richardson RC, Hahn EA, Chrisman CL. Diagnostic and prognostic importance of chromosomal aberrations identified in 61 dogs with lymphosarcoma. Vet Patho 31: 528-540, 1994. 52. Hardy WD. Hematopoietic tumors of cats. J Am Anim Hosp Assoc 17: 921-940, 1981. 53. Hargis AM, Thomassen RW, Phemister RD. Chronic dermatosis and cutaneous squamous cell carcinoma in the beagle dog. Vet Patho 14: 218-228, 1977. 54. Hauck ML. Tumors of the Skin and Subcutaneous Tissues. In: Withrow SJ, Vail DM, and Page R, ed. Withrow and MacEwen's small animal clinical oncology. 5th ed. Elsevier Saunders, St. Louis, 305-320, 2013. 55. Head KW, Else RW, Dubielzig RR. Tumors of the alimentary tract. In: Meuten DJ, ed. Tumors in domestic animals. 4th ed. Blackwell Publishing Company, Iowa, 401-482, 2002. 56. Hennipman A, Van Oirschot BA, Smits J, Rijksen G, Staal GE. Glycolytic enzyme activities in breast cancer metastases. Tumor Biol 9: 241-248, 1988. 57. Himsel CA, Richardson R, Craig J. Cisplatin chemotherapy for metastatic squamous cell carcinoma in two dogs. J Am Vet Med Assoc 189: 1575-1578, 1986. 58. Jacobs RM, Messick JB, Valli VE. Tumors of the hemolymphatic system. In: Meuten DJ, ed. Tumors in domestic animals. 4th ed. Blackwell Publishing Company, Iowa, 119-198, 2002. 59. Jagielski D, Lechowski R, Hoffmann-Jagielska M, Winiarczyk S. A retrospective study of the incidence and prognostic factors of multicentric lymphoma in dogs (1998–2000). J Vet Med Ser A 49: 419-424, 2002. 60. Jiang BH, Agani F, Passaniti A, Semenza GL. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res 57: 5328-5335, 1997. 61. Keller A, Demeurie J, Merkulova T, Geraud G, Cywiner‐Golenzer C, Lucas M, Chatelet FP. Fibre‐type distribution and subcellular localisation of α and β enolase in mouse striated muscle. Biol Cell 92: 527-535, 2000. 62. Keller A, Peltzer J, Carpentier G, Horvath I, Olah J, Duchesnay A, Orosz F, Ovadi J. Interactions of enolase isoforms with tubulin and microtubules during myogenesis. BBA-Gen Subjects 1770: 919-926, 2007. 63. Keller ET, MacEwen EG, Rosenthal RC, Helfand SC, Fox LE. Evaluation of prognostic factors and sequential combination chemotherapy with doxorubicin for canine lymphoma. J Vet Intern Med 7: 289-295, 1993. 64. Khanna M, Fortier‐Riberdy G, Smoller B, Dinehart S. Reporting tumor thickness for cutaneous squamous cell carcinoma. J Cutan Pathol 29: 321-323, 2002. 65. Kitchell BE, Brown DM, Luck EE, Woods LL, Orenberg EK, Bloch DA. Intralesional implant for treatment of primary oral malignant melanoma in dogs. J Am Vet Med Assoc 204: 229-236, 1994. 66. Kiupel M, Bostock D, Bergmann V. The prognostic significance of AgNOR counts and PCNA-positive cell counts in canine malignant lymphomas. J Comp Pathol 119: 407-418, 1998. 67. Kiupel M, Teske E, Bostock D. Prognostic factors for treated canine malignant lymphoma. Vet Patho 36: 292-300, 1999. 68. Knapp DW, Richardson RC, Chan TC, Bottoms GD, Widmer WR, DeNicola DB, Teclaw R, Bonney P, Kuczek T. Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. J Vet Intern Med 8: 273-278, 1994. 69. Kumar V, Sharma A. Mast cells: emerging sentinel innate immune cells with diverse role in immunity. Mol Immunol 48: 14-25, 2010. 70. LaDue‐Miller T, Price GS, Page RL, Thrall DE. Radiotherapy of canine non-tonsillar squamous cell carcinoma. Vet Radiol Ultrasound 37: 74-77, 1996. 71. Lagunoff D, Benditt EP. Proteolytic enzymes of mast cells. Ann N Y Acad Sci 103: 185-198, 1963. 72. Lana SE, Ogilvie GK, Withrow SJ, Straw RC, Rogers KS. Feline cutaneous squamous cell carcinoma of the nasal planum and the pinnae: 61 cases. J Am Anim Hosp Assoc 33: 329-332, 1997. 73. Laprie C, Abadie J, Amardeilh MF, Net JL, Lagadic M, Delverdier M. MIB‐1 immunoreactivity correlates with biologic behaviour in canine cutaneous melanoma. Vet Dermatol 12: 139-147, 2001. 74. Larsen TE, Grude TH. A retrospective histological study of 669 cases of primary cutaneous malignant melanoma in clinical stage I. Acta Pathol Microbiol Immunol Scand A 86: 437-450, 1978. 75. Lascelles BDX, Henderson RA, Seguin B, Liptak JM, Withrow SJ. Bilateral rostral maxillectomy and nasal planectomy for large rostral maxillofacial neoplasms in six dogs and one cat. J Am Anim Hosp Assoc 40: 137-146, 2004. 76. Lascelles BDX, Parry AT, Stidworthy MF, Dobson JM, White RA. Squamous cell carcinoma of the nasal planum in 17 dogs. Vet Rec 147: 473-476, 2000. 77. Liptak JM, Withrow SJ. Cancer of the gastrointestinal tract. In: Withrow SJ, Vail DM, and Page R, ed. Withrow and MacEwen's small animal clinical oncology. 5th ed. Elsevier Saunders, St. Louis, 381-430, 2013. 78. Liu KJ, Shih NY. The role of enolase in tissue invasion and metastasis of pathogens and tumor cells. J Cancer Mol 3: 45-48, 2007. 79. London C, Mathie T, Stingle N, Clifford C, Haney S, Klein MK, Beaver L, Vickery K, Vail DM, Hershey B. Preliminary evidence for biologic activity of toceranib phosphate (PalladiaR) in solid tumours. Vet Comp Oncol 10: 194-205, 2012. 80. London CA, Hannah AL, Zadovoskaya R, Chien MB, Kollias-Baker C, Rosenberg M, Downing S, Post G, Boucher J, Shenoy N. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clin Cancer Res 9: 2755-2768, 2003. 81. London CA, Thamm DH. Mast cell tumors. In: Withrow SJ, Vail DM, and Page RL, ed. Withrow and MacEwen's small animal clinical oncology. 5th ed. Elsevier Saunders, St. Louis, 335-355, 2013. 82. MacEwen EG, Patnaik A, Harvey H, Hayes A, Matus R. Canine oral melanoma: comparison of surgery versus surgery plus Corynebacterium parvum. Cancer Invest 4: 397-402, 1986. 83. Macy DW. Canine and feline mast cell tumors: biologic behavior, diagnosis, and therapy. Semin Vet Med Surg (Small Anim) 1: 72-83, 1986. 84. Mahony OM, Moore AS, Cotter SM, Engler SJ, Brown D, Penninck DG. Alimentary lymphoma in cats: 28 cases (1988-1993). J Am Vet Med Assoc 207: 1593-1598, 1995. 85. Martin CK, Tannehill-Gregg SH, Wolfe TD, Rosol TJ. Bone-invasive oral squamous cell carcinoma in cats pathology and expression of parathyroid hormone-related protein. Vet Patho 48: 302-312, 2011. 86. McNiel EA, Prink AL, O'Brien TD. Evaluation of risk and clinical outcome of mast cell tumours in pug dogs. Vet Comp Oncol 4: 2-8, 2006. 87. Meleo KA. The role of radiotherapy in the treatment of lymphoma and thymoma. Vet Clin North Am Small Anim Pract 27: 115-129, 1997. 88. Meleti M, Leemans CR, Mooi WJ, Vescovi P, van der Waal I. Oral malignant melanoma: a review of the literature. Oral Oncol 43: 116-121, 2007. 89. Metz M, Piliponsky AM, Chen CC, Lammel V, Abrink M, Pejler G, Tsai M, Galli SJ. Mast cells can enhance resistance to snake and honeybee venoms. Science 313: 526-530, 2006. 90. Michels GM, Knapp DW, DeNicola DB, Glickman N, Bonney P. Prognosis following surgical excision of canine cutaneous mast cell tumors with histopathologically tumor-free versus nontumor-free margins: a retrospective study of 31 cases. J Am Anim Hosp Assoc 38: 458-466, 2002. 91. Miles LA, Dahlberg CM, Plescia J, Felez J, Kato K, Plow EF. Role of cell-surface lysines in plasminogen binding to cells: identification of alpha-enolase as a candidate plasminogen receptor. Biochemistry 30: 1682-1691, 1991. 92. Millanta F, Fratini F, Corazza M, Castagnaro M, Zappulli V, Poli A. Proliferation activity in oral and cutaneous canine melanocytic tumours: correlation with histological parameters, location, and clinical behaviour. Res Vet Sci 73: 45-51, 2002. 93. Miller MA, Nelson SL, Turk JR, Pace LW, Brown TP, Shaw DP, Fischer JR, Gosser HS. Cutaneous neoplasia in 340 cats. Vet Patho 28: 389-395, 1991. 94. Mooney SC, Hayes AA, MacEwen EG, Matus RE, Geary A, Shurgot BA. Treatment and prognostic factors in lymphoma in cats: 103 cases (1977-1981). J Am Vet Med Assoc 194: 696-702, 1989. 95. Moore AS, Cotter SM, Rand WM, Wood CA, Williams LE, London CA, Frimberger AE, L'Heureux DA. Evaluation of a discontinuous treatment protocol (VELCAP‐S) for canine lymphoma. J Vet Intern Med 15: 348-354, 2001. 96. Moscato S, Pratesi F, Sabbatini A, Chimenti D, Scavuzzo M, Passantino R, Bombardieri S, Giallongo A, Migliorini P. Surface expression of a glycolytic enzyme, α‐enolase, recognized by autoantibodies in connective tissue disorders. Eur J Immunol 30: 3575-3584, 2000. 97. Murphy S, Hayes AM, Blackwood L, Maglennon G, Pattinson H, Sparkes AH. Oral malignant melanoma–the effect of coarse fractionation radiotherapy alone or with adjuvant carboplatin therapy. Vet Comp Oncol 3: 222-229, 2005. 98. Murphy S, Sparkes AH, Brearley MJ, Smithen KC, Blunden AS. Relationships between the histological grade of cutaneous mast cell tumours in dogs, their survival and the efficacy of surgical resection. Vet Rec 154: 2004. 99. Nasir L, Krasner H, Argyle DJ, Williams A. Immunocytochemical analysis of the tumour suppressor protein (p53) in feline neoplasia. Cancer Lett 155: 1-7, 2000. 100. Nathaniel III CM, Moore AS, Rand WM, Gliatto J, Cotter SM. Evaluation of a multidrug chemotherapy protocol (ACOPA II) in dogs with lymphoma. J Vet Intern Med 11: 333-339, 1997. 101. NCI. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas. Cancer 49: 2112-2135, 1982. 102. Pancholi V. Multifunctional α-enolase: its role in diseases. Cell Mol Life Sci 58: 902-920, 2001. 103. Patnaik AK, Ehler WJ, MacEwen EG. Canine cutaneous mast cell tumor: morphologic grading and survival time in 83 dogs. Vet Patho 21: 469-474, 1984. 104. Peebles KA, Duncan MW, Ruch RJ, Malkinson AM. Proteomic analysis of a neoplastic mouse lung epithelial cell line whose tumorigenicity has been abrogated by transfection with the gap junction structural gene for connexin 43, Gja1. Carcinogenesis 24: 651-657, 2003. 105. Proulx DR, Ruslander DM, Dodge RK, Hauck ML, Williams LE, Horn B, Sylvester Price G, Thrall DE. A retrospective analysis of 140 dogs with oral melanoma treated with external beam radiation. Vet Radiol Ultrasound 44: 352-359, 2003. 106. Ramos-Vara JA, Beissenherz ME, Miller MA, Johnson GC, Pace LW, Fard A, Kottler SJ. Retrospective study of 338 canine oral melanomas with clinical, histologic, and immunohistochemical review of 129 cases. Vet Patho 37: 597-608, 2000. 107. Ramos-Vara JA, Miller MA. Immunohistochemical identification of canine melanocytic neoplasms with antibodies to melanocytic antigen PNL2 and Tyrosinase comparison with Melan A. Vet Patho 48: 443-450, 2011. 108. Ray RB, Steele R, Seftor E, Hendrix M. Human breast carcinoma cells transfected with the gene encoding a c-myc promoter-binding protein (MBP-1) inhibits tumors in nude mice. Cancer Res 55: 3747-3751, 1995. 109. Redlitz A, Fowler BJ, Plow EF, Miles LA. The role of an enolase‐related molecule in plasminogen binding to cells. Eur J Biochem 227: 407-415, 1995. 110. Reed JH. The occurrence of tumors in domestic animals. Can Vet J 23: 71, 1982. 111. Rode J, Dhillon AP. Neurone specific enolase and S100 protein as possible prognostic indicators in melanoma. Histopathology 8: 1041-1052, 1984. 112. Rogers KS. Mast cell tumors: dilemmas of diagnosis and treatment. Vet Clin North Am Small Anim Pract 26: 87-102, 1996. 113. Rosenberg MP, Matus RE, Patnaik AK. Prognostic factors in dogs with lymphoma and associated hypercalcemia. J Vet Intern Med 5: 268-271, 1991. 114. Royds JA, Parsons MA, Rennie IG, Timperley WR, Taylor CB. Enolase isoenzymes in benign and malignant melanocytic lesions. Diagn Histopathol 5: 175-181, 1981. 115. Ruslander D, KaserHotz B, Sardinas JC. Cutaneous squamous cell carcinoma in cats. Comp Cont Educ Pract Vet 19: 1119-1129, 1997. 116. Sabattini S, Marconato L, Zoff A, Morini M, Scarpa F, Capitani O, Bettini G. Epidermal growth factor receptor expression is predictive of poor prognosis in feline cutaneous squamous cell carcinoma. J Feline Med Surg 12: 760-768, 2010. 117. Schmidt BR, Glickman NW, DeNicola DB, Gortari AEd, Knapp DW. Evaluation of piroxicam for the treatment of oral squamous cell carcinoma in dogs. J Am Vet Med Assoc 218: 1783-1786, 2001. 118. Schultheiss PC. Histologic features and clinical outcomes of melanomas of lip, haired skin, and nail bed locations of dogs. J Vet Diagn Invest 18: 422-425, 2006. 119. Schwarz PD, Withrow SJ, Curtis CR, Powers BE, Straw RC. Mandibular resection as a treatment for oral cancer in 81 dogs. J Am Anim Hosp Assoc 27: 1991. 120. Schwarz PD, Withrow SJ, Curtis CR, Powers BE, Straw RC. Partial maxillary resection as a treatment for oral cancer in 61 dogs. J Am Anim Hosp Assoc 27: 1991. 121. Semenza GL, Jiang BH, Leung SW, Passantino R, Concordet JP, Maire P, Giallongo A. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem 271: 32529-32537, 1996. 122. Simpson AM, Ludwig LL, Newman SJ, Bergman PJ, Hottinger HA, Patnaik AK. Evaluation of surgical margins required for complete excision of cutaneous mast cell tumors in dogs. J Am Vet Med Assoc 224: 236-240, 2004. 123. Smedley RC, Spangler WL, Esplin DG, Kitchell BE, Bergman PJ, Ho HY, Bergin IL, Kiupel M. Prognostic markers for canine melanocytic neoplasms a comparative review of the literature and goals for future investigation. Vet Patho 48: 54-72, 2011. 124. Smith SH, Goldschmidt MH, McManus PM. A comparative review of melanocytic neoplasms. Vet Patho 39: 651-678, 2002. 125. Stiglmair-Herb MT. Hauttumoren bei Katzen-eine retrospektive Studie. Tierarztl Umschau 42: 681-686, 1987. 126. Stone MS, Goldstein MA, Cotter SM. Comparison of two protocols for induction of remission in dogs with lymphoma. J Am Anim Hosp Assoc 315-321, 1991. 127. Strefezzi RF, Kleeb SR, Xavier JG, Catao-Dias JL. Prognostic indicators for mast cell tumors. Braz J Vet Pathol 2: 110-121, 2009. 128. Takashima M, Kuramitsu Y, Yokoyama Y, Iizuka N, Fujimoto M, Nishisaka T, Okita K, Oka M, Nakamura K. Overexpression of alpha enolase in hepatitis C virus‐related hepatocellular carcinoma: Association with tumor progression as determined by proteomic analysis. Proteomics 5: 1686-1692, 2005. 129. Takikita M, Altekruse S, Lynch CF, Goodman MT, Hernandez BY, Green M, Cozen W, Cockburn M, Saber MS, Topor M. Associations between selected biomarkers and prognosis in a population-based pancreatic cancer tissue microarray. Cancer Res 69: 2950-2955, 2009. 130. Teifke JP, Lohr CV. Immunohistochemical detection of P53 overexpression in paraffin wax-embedded squamous cell carcinomas of cattle, horses, cats and dogs. J Comp Pathol 114: 205-210, 1996. 131. Teifke JP, Lohr CV, Shirasawa H. Detection of canine oral papillomavirus-DNA in canine oral squamous cell carcinomas and p53 overexpressing skin papillomas of the dog using the polymerase chain reaction and non-radioactive in situ hybridization. Vet Microbiol 60: 119-130, 1998. 132. Teske E. Canine malignant lymphoma: A review and comparison with human non‐hodgkin's lymphoma. Vet Quart 16: 209-219, 1994. 133. Teske E, Van Heerde P, Rutteman GR, Kurzman ID, Moore PF, MacEwen EG. Prognostic factors for treatment of malignant lymphoma in dogs. J Am Vet Med Assoc 205: 1722-1728, 1994. 134. Thamm DH, Mauldin EA, Vail DM. Prednisone and vinblastine chemotherapy for canine mast cell tumor—41 cases (1992–1997). J Vet Intern Med 13: 491-497, 1999. 135. Theon AP, Madewell BR, Shearn VI, Moulton JE. Prognostic factors associated with radiotherapy of squamous cell carcinoma of the nasal plane in cats. J Am Vet Med Assoc 206: 991-996, 1995. 136. Theon AP, Rodriguez C, Madewell BR. Analysis of prognostic factors and patterns of failure in dogs with malignant oral tumors treated with megavoltage irradiation. J Am Vet Med Assoc 210: 778-784, 1997. 137. Theon AP, VanVechten MK, Madewell BR. Intratumoral administration of carboplatin for treatment of squamous cell carcinomas of the nasal plane in cats. Am J Vet Res 57: 205-210, 1996. 138. Todoroff RJ, Brodey RS. Oral and pharyngeal neoplasia in the dog: a retrospective survey of 361 cases. J Am Vet Med Assoc 175: 567-571, 1979. 139. Tsai ST, Chien I, Shen WH, Kuo YZ, Jin YT, Wong TY, Hsiao JR, Wang HP, Shih NY, Wu LW. ENO1, a potential prognostic head and neck cancer marker, promotes transformation partly via chemokine CCL20 induction. Eur J Cancer 46: 1712-1723, 2010. 140. Tu SH, Chang CC, Chen CS, Tam KW, Wang YJ, Lee CH, Lin HW, Cheng TC, Huang CS, Chu JS. Increased expression of enolase α in human breast cancer confers tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat 121: 539-553, 2010. 141. Vail DM, Macewen EG. Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Invest 18: 781-792, 2000. 142. Vail DM, Pinkerton ME, Young KM. Hematopoietic tumors. In: Withrow SJ, Vail DM, and Page RL, ed. Withrow and MacEwen's small animal clinical oncology. 5th ed. Elsevier Saunders, St. Louis, 608-678, 2013. 143. Villamil JA, Henry CJ, Hahn AW, Bryan JN, Tyler JW, Caldwell CW. Hormonal and sex impact on the epidemiology of canine lymphoma. J Cancer Epidemiol 2009: e591753, 2009. 144. Wallace J, Matthiesen DT, Pantnaik AK. Hemimaxillectomy for the treatment of oral tumors in 69 dogs. Vet Surg 21: 337-341, 1992. 145. Watrach AM, Small E, Case MT. Canine papilloma: progression of oral papilloma to carcinoma. J Natl Cancer Inst 45: 915-920, 1970. 146. Webster JD, Yuzbasiyan-Gurkan V, Kaneene JB, Miller R, Resau JH, Kiupel M. The role of c-KIT in tumorigenesis: evaluation in canine cutaneous mast cell tumors. Neoplasia 8: 104, 2006. 147. Webster JD, Yuzbasiyan-Gurkan V, Thamm DH, Hamilton E, Kiupel M. Evaluation of prognostic markers for canine mast cell tumors treated with vinblastine and prednisone. BMC Vet Res 4: 32, 2008. 148. Welle MM, Bley CR, Howard J, Rufenacht S. Canine mast cell tumours: a review of the pathogenesis, clinical features, pathology and treatment. Vet Dermatol 19: 321-339, 2008. 149. Williams LS, Mancuso AA, Mendenhall WM. Perineural spread of cutaneous squamous and basal cell carcinoma: CT and MR detection and its impact on patient management and prognosis. Int J Radiat Oncol Biol Phys 49: 1061-1069, 2001. 150. Wu W, Tang X, Hu W, Lotan R, Hong WK, Mao L. Identification and validation of metastasis-associated proteins in head and neck cancer cell lines by two-dimensional electrophoresis and mass spectrometry. Clin Exp Metastasis 19: 319-326, 2002. 151. Wygrecka M, Marsh LM, Morty RE, Henneke I, Guenther A, Lohmeyer J, Markart P, Preissner KT. Enolase-1 promotes plasminogen-mediated recruitment of monocytes to the acutely inflamed lung. Blood 113: 5588-5598, 2009. 152. Young B, Woodford P, O'Dowd G. Eputhelial tissue. In: Wheater's functional histology: a text and colour atlas. 6th ed. Elsevier Churchill Livingstone, Philadelphia, 82-100, 2013. 153. Young B, Woodford P, O'Dowd G. Immune system. In: Wheater's functional histology: a text and colour atlas. 6th ed. Elsevier Churchill Livingstone, Philadelphia, 197-223, 2013. 154. Young B, Woodford P, O'Dowd G. Skin. In: Wheater's functional histology: a text and colour atlas. 6th ed. Elsevier Churchill Livingstone, Philadelphia, 159-179, 2013. 155. Zaugg N, Nespeca G, Hauser B, Ackermann M, Favrot C. Detection of novel papillomaviruses in canine mucosal, cutaneous and in situ squamous cell carcinomas. Vet Dermatol 16: 290-298, 2005. 156. Zhang L, Cilley RE, Chinoy MR. Suppression subtractive hybridization to identify gene expressions in variant and classic small cell lung cancer cell lines. J Surg Res 93: 108-119, 2000. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/58047 | - |
| dc.description.abstract | 甲型烯醇酶 (alpha-enolase, ENO1)為一個物種演化高度保留之蛋白，且是一種醣解酵素。在細胞表面的ENO1作為胞漿素原(plasminogen)受體，幫助腫瘤細胞消化周圍的纖維結締組織，而達到入侵基質的目的，此功能被認為與腫瘤的入侵基質及轉移的能力有關。目前在醫學界對ENO1的研究，發現在高度惡性或有轉移性的肺癌及頭頸部的腫瘤，其ENO1基因的表現性有增強的現象；而在胰臟癌、肺小細胞癌、C型肝炎病毒所引發的肝癌及乳癌等，發現ENO1過度表現與癌症惡化程度有關。在獸醫學的研究，指出ENO1過度表現的犬惡性乳房腫瘤預後較差、存活期較短，在統計學上有顯著相關性。故希望以研究犬惡性乳房腫瘤的方式，探討ENO1在犬貓其他腫瘤的表現， ENO1表現是否與惡性程度及預後有關。
本研究藉由免疫組織化學染色配合Quick score評估，以卡方檢定探討ENO1過度表現與病理學上的相關性，並以Kaplan-Meier分析生存曲線，評估ENO1是否能成為犬貓腫瘤的可能預後因子。選定下列四種在犬貓較常見的腫瘤：鱗狀上皮細胞癌、肥大細胞瘤、淋巴瘤及黑色素瘤，以回溯性研究的方式，收集四種腫瘤之臨床及病理資訊。在收集的病例中，鱗狀上皮細胞癌：犬31例、貓7例；肥大細胞瘤：犬54例、貓5例；淋巴瘤：犬25例、貓7例；以及黑色素瘤：犬57例。結果顯示在犬鱗狀上皮細胞癌，當ENO1過度表現時，與腫瘤等級較惡性及較差的細胞分化有顯著相關，且有顯著較短的存活時間。在犬肥大細胞瘤，ENO1過度表現與年齡較小有顯著相關。在犬淋巴瘤，當ENO1過度表現時也有顯著較短的存活時間。在犬黑色素瘤，當ENO1過度表現時，與腫瘤細胞分化較差及有絲分裂相較旺盛有顯著相關，且有顯著較短的存活時間。因此，本研究顯示，ENO1過度表現應可做為犬鱗狀上皮細胞癌、犬淋巴瘤及犬黑色素瘤的預後評估因子。 | zh_TW |
| dc.description.abstract | Alpha-enolase (ENO1) is an evolutionally-conserved protein and a key glycolytic enzyme. ENO1 is found on the tumor cell surfaces and functions as one of the plasminogen receptors. Then it further degrades fibrin and several extracellular matrix components. It is implicating that it may be involved in tissue invasion during tumor metastasis. In recent years, upregulation of ENO1 gene has been observed in several highly tumorigenic or metastatic cell lines, including small cell lung cancer, head and neck cancer. In addition, its overexpression has been also suggested to be a prognostic biomarker in several types of human cancers such as non-small cell lung cancer, pancreatic carcinoma, hepatitis C virus -related hepatocellular carcinoma and breast cancer. In veterinary medicine, recently published research revealed that overexpression of ENO1 is detected in tumor cells of canine mammary carcinoma and significantly correlated with shorter survival. Based on previous study, we follow the canine mammary carcinoma study to investigate the ENO1 expression in other tumors and to verify whether ENO1 expression statuses are related to their malignancy or poor outcome.
In this study, we investigated the ENO1 expression by immunohistochemistry and quantified by Quick score. Correlations of ENO1 overexpression and clinicopathologic parameters of tumors were examined by Pearson's chi-square test. Cause-specific survival was calculated by Kaplan-Meier analysis to verify whether ENO1 expression statuses can be a prognostic factor of other tumors. Four common tumors in dogs and cats including squamous cell carcinoma (SCC), mast cell tumor (MCT), lymphoma, and melanoma were retrospectively retrieved with their clinical and pathological information. A total of 38 cases of SCCs (31 dogs and 7 cats), 59 cases of MCTs (54 dogs and 5 cats), 32 cases of lymphomas (25 dogs and 7 cats) and 57 cases of canine melanomas were included. The results revealed that in canine SCCs, ENO1 overexpression was significantly correlation with higher grade, poorer tumor cell differentiation and shorter cause-specific survival. In canine lymphomas, ENO1 overexpression was significantly correlation with shorter cause-specific survival. In canine MCTs, ENO1 overexpression was significantly correlation with younger age. In canine melanomas, ENO1 overexpression was significantly correlation with poorer cell differentiation, higher mitotic activity and shorter cause-specific. Thus, ENO1 overexpression may be used as a biomarker for poorer prognosis in canine SCCs, lymphomas and melanomas. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-16T08:05:04Z (GMT). No. of bitstreams: 1 ntu-103-R01644004-1.pdf: 1771274 bytes, checksum: 43dc1c6a3fedcb9602465fafea0cc438 (MD5) Previous issue date: 2014 | en |
| dc.description.tableofcontents | 中文摘要 I
Abstract II Chapter 1. Introduction 1 Chapter 2. Background and Literature Review 4 2.1 Squamous cell carcinoma (SCC) 4 2.1.1 Squamous epithelium physiology and histology 4 2.1.2 Incidence and predilection 4 2.1.3 Risk factor 5 2.1.4 Clinical presentation 6 2.1.5 Histological classification 6 2.1.6 Prognostic factors 8 2.1.7 Treatment 9 2.2 Mast cell tumor (MCT) 11 2.2.1 Mast cell physiology and histology 11 2.2.2 Incidence and predilection 11 2.2.3 Clinical presentation 12 2.2.4 Histological classification 13 2.2.5 Prognostic factors 14 2.2.6 Treatment 15 2.3 Lymphoma 16 2.3.1 Lymphocyte physiology and histology 16 2.3.2 Incidence and predilection 16 2.3.3 Clinical presentation 17 2.3.4 Histological classification 19 2.3.5 Prognostic factors 20 2.3.6 Treatment 21 2.4 Melanoma 22 2.4.1 Melanocyte physiology and histology 22 2.4.2 Incidence and predilection 22 2.4.3 Clinical presentation 23 2.4.4 Histological classification 24 2.4.5 Prognostic factors 25 2.4.6 Treatment 26 2.5 Alpha-enolase (ENO1) 27 Chapter 3. Materials and Methods 32 3.1 Case collection 32 3.2 Histological evaluation 33 3.3 Immunohistochemistry (IHC) 34 3.4 Evaluation of immunoreactivity 35 3.5 Immunoblotting 36 3.6 Statistical analysis 37 Chapter 4. Result 39 4.1 Squamous cell carcinomas 39 4.1.1 Patients 39 4.1.2 Histological evaluation 40 4.1.3 Immunostaining (ENO1 expression) evaluation 40 4.1.4 Survival data 42 4.2 Mast cell tumors 42 4.2.1 Patients 42 4.2.2 Histological evaluation 43 4.2.3 Immunostaining (ENO1 expression) evaluation 44 4.2.4 Survival data 45 4.3 Lymphomas 45 4.3.1 Patients 45 4.3.2 Histological evaluation 46 4.3.3 Immunostaining (ENO1 expression) evaluation 47 4.3.4 Survival data 48 4.4 Melanomas 49 4.4.1 Patients 49 4.4.2 Histological evaluation 50 4.4.3 Immunostaining (ENO1 expression) evaluation 50 4.4.4 Survival data 52 4.5 Immunoblotting (ENO1 expression) evaluation 53 Chapter 5. Discussion 54 Tables 63 Table 1. Bryne’s grading system for squamous cell carcinoma (1992)* 63 Table 2. Histological classification for Mast cell tumor of Patnailk system (1984)* 64 Table 3. The Working Formulation classification (1982) 65 Table 4. The staging system of Clark level (1969) 66 Table 5. TNM clinical staging system for head and neck mucosal melanomas with histopathological microstaging for Stage I 66 Table 6. Signalments of the 31 dogs with squamous cell carcinomas 67 Table 7. Signalments of the 7 cats with squamous cell carcinomas 68 Table 8. Signalments of the 54 dogs with mast cell tumors 69 Table 9. Signalments of the 5 cats with mast cell tumors 70 Table 10. Signalments of the 25 dogs with lymphomas 71 Table 11. Signalments of the 7 cats with lymphomas 72 Table 12. Signalments of the 57 dogs with melanomas 73 Table 13. Correlation between ENO1 overexpression and clinicopathologic characteristics of canine squamous cell carcinomas by Pearson's chi-square test 74 Table 14. Correlation between ENO1 overexpression and clinicopathologic characteristics of feline squamous cell carcinomas by Pearson's chi-square test 75 Table 15. Correlation between ENO1 overexpression and clinicopathologic characteristics of canine mast cell tumors by Pearson's chi-square test 76 Table 16. Correlation between ENO1 overexpression and clinicopathologic characteristics of feline mast cell tumors by Pearson's chi-square test 77 Table 17. Correlation between ENO1 overexpression and clinicopathologic characteristics of canine lymphomas by Pearson's chi-square test 78 Table 18. Correlation between ENO1 overexpression and clinicopathologic characteristics of feline lymphomas by Pearson's chi-square test 79 Table 19. Correlation between ENO1 overexpression and clinicopathologic characteristics of canine melanomas by Pearson's chi-square test 80 Table 20. Correlation between ENO1 overexpression and clinicopathologic characteristics of canine mucosal melanomas by Pearson's chi-square test 81 Table 21. Correlation between ENO1 overexpression and clinicopathologic characteristics of canine cutaneous melanomas by Pearson's chi-square test 82 Table 22. Overexpression of ENO1 and age in the Cox regression model for predicting cause-specific survival in canine squamous cell carcinomas 83 Table 23. Overexpression of ENO1 and age in the Cox regression model for predicting cause-specific survival in canine lymphomas 83 Table 24. Overexpression of ENO1 and age in the Cox regression model for predicting cause-specific survival in canine melanomas 83 Figures 84 Figure 1. ENO1 expressed in squamous cell carcinomas and other tissue. (ENO1 immunohistochemical stain, DAB chromogen, hematoxylin counterstain) 84 Figure 2. ENO1 expressed in mast cell tumors. (ENO1 immunohistochemical stain, DAB chromogen, hematoxylin counterstain) 85 Figure 3. ENO1 expressed in lymphomas. (ENO1 immunohistochemical stain, Fast Red chromogen, hematoxylin counterstain) 86 Figure 4. ENO1 expressed in melanomas. (ENO1 immunohistochemical stain, Fast Red chromogen, hematoxylin counterstain) 87 Figure 5. Kaplan-Meier curves for cause-specific survival of 24 canine squamous cell carcinomas patients with and without ENO1 overexpression. 88 Figure 6. Kaplan-Meier curves for cause-specific survival of 7 feline squamous cell carcinomas patients with and without ENO1 overexpression. 89 Figure 7. Kaplan-Meier curves for cause-specific survival of 33 canine mast cell tumors patients with and without ENO1 overexpression. 90 Figure 8. Kaplan-Meier curves for cause-specific survival of 14 canine lymphomas patients with and without ENO1 overexpression. 91 Figure 9. Kaplan-Meier curves for cause-specific survival of 5 feline lymphomas patients with and without ENO1 overexpression. 92 Figure 10. Kaplan-Meier curves for cause-specific survival of 36 canine melanomas patients with and without ENO1 overexpression. 93 Figure 11. Kaplan-Meier curves for cause-specific survival of 28 canine mucosal melanomas patients with and without ENO1 overexpression. 94 Figure 12. Kaplan-Meier curves for cause-specific survival of 5 canine cutaneous melanomas patients with and without ENO1 overexpression. 95 Figure 13. Immunoblot analysis for ENO1 96 References 97 Appendix 1 109 Appendix 2 112 Appendix 3 115 Appendix 4 118 | |
| dc.language.iso | en | |
| dc.title | 犬貓腫瘤之甲型烯醇蛋白表現與其預後和組織病理學之相關性 | zh_TW |
| dc.title | Alpha-Enolase (ENO1) Expression and Its Correlation with Prognosis and Histopathology in Tumors of Dogs and Cats | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 102-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 廖泰慶(Albert Tai-Ching Liao),林正忠(Cheng-Chung Lin),朱旆億(Pei-Yi Chu) | |
| dc.subject.keyword | 甲型烯醇,犬,貓,鱗狀上皮細胞癌,肥大細胞瘤,淋巴瘤,黑色素瘤,免疫組織化學染色,預後, | zh_TW |
| dc.subject.keyword | Alpha-enolase (ENO1),canine,feline,squamous cell carcinoma (SCC),mast cell tumor (MCT),lymphoma,melanoma,immunohistochemistry,prognosis, | en |
| dc.relation.page | 121 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2014-06-26 | |
| dc.contributor.author-college | 獸醫專業學院 | zh_TW |
| dc.contributor.author-dept | 分子暨比較病理生物學研究所 | zh_TW |
| 顯示於系所單位： | 分子暨比較病理生物學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-103-1.pdf 目前未授權公開取用 | 1.73 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。